Stock Report

JB Chemicals & Pharmaceuticals Ltd records revenue growth of 11% to INR 1065 crores in Q3 FY26

Posted On : 2026-01-17 09:59:15( TIMEZONE : IST )

JB Chemicals & Pharmaceuticals Ltd (JB Pharma), one of the fastest growing pharmaceutical companies in India, announced its financial results for the quarter ended 31st December 2025.

Quarterly Financial Performance - Q3 FY26 vs Q3 FY25

JB Pharma recorded revenue of INR 1,065 crores in the third quarter of FY26, registering growth of 11% from INR 963 crores in Q3 FY25. Operating EBITDA* (Earnings before Interest, Depreciation and Taxes) increased by 13% to INR 305 crores compared to INR 270 crores in the same quarter last year. Net Profit rose by 22% to INR 198 crores versus INR 162 crores in Q3 FY25.

*Operating EBITDA is after excluding non-cash ESOP charge and one off charges

Commenting on the financial results, Mr. Nikhil Chopra, CEO and Wholetime Director, JB Pharma stated "JB Pharma's domestic formulations business, once again outperformed the Indian pharmaceutical market, driven by broad-based momentum across key chronic therapies and continued strength in our flagship brands. On the international front, while the CDMO business continued its positive momentum, the international formulations business also recorded strong growth in several key markets.

Our focus on cost optimization, favourable product mix and operational efficiencies led to improved operating margins for Q3 FY26 as well as for 9M FY26. With a strong balance sheet, net cash position, and sustained cash flow generation, we remain confident in our ability to deliver profitable growth. As we move forward, our priorities remain centered on strengthening flagship brand franchises, accelerating growth in chronic therapies, scaling our CDMO businesses, and building a resilient, agile, and future-ready organization."

Financial Performance - 9M FY26 vs 9M FY25

For the first nine months of the financial year 2025-26, the Company recorded revenue of INR 3244 crores as compared to INR 2969 crores, registering growth of 9%. Operating EBITDA* (Earnings Before Interest Depreciation and Taxes) increased by 13% to INR 955 crores as compared to INR 846 crores. Profit after Tax registered growth of 18% to INR 608 crores in 9M FY26 vs INR 514 crores in 9M FY25.